Clostridium difficile infection: new developments in epidemiology and pathogenesis
The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
Clostridium difficile is now considered to be one of the most important causes of health care-associated infections. C. difficile infections are also emerging in the community and in animals used for food, and are no longer viewed simply as unpleasant complications that follow antibiotic therapy. Since 2001, the prevalence and severity of C. difficile infection has increased significantly, which has led to increased research interest and the discovery of new virulence factors, and has expanded and focused the development of new treatment and prevention regimens. This Review summarizes the recent epidemiological changes in C. difficile infection, our current knowledge of C. difficile virulence factors and the clinical outcomes of C. difficile infection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, studies have demonstrated that patients suffering from recurrent CDI are deficient in phyla of bacteria normally dominant in the colon6,45 (Figure 1).”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [45]
Citations
Cites
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361 · cited 1×
“It is becoming evident from 16S ribosomal RNA sequencing that disruption of the gut microbiota following antibiotic treatment is much greater than was previously realize”
BackgroundAn Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Interventions to improve antibiotic prescribing practices for hospital inpatients
Davey, P., Brown, E., Charani, E., Fenelon, L., Gould, I. M., Holmes, A., Ramsay, C. R., Wiffen, P. J., & Wilcox, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003543.pub3 · Cited by 1,864
Nosocomial Acquisition of Clostridium difficile Infection
McFarland, L. V., Mulligan, M. E., Kwok, R. Y. Y., & Stamm, W. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901263200402 · Cited by 1,326
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Glucosylation of Rho proteins by Clostridium difficile toxin B
Just, I., Selzer, J., Wilm, M., Eichel-Streiber, C. V., Mann, M., & Aktories, K. (1995) · Nature · doi:10.1038/375500a0 · Cited by 1,032
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Research works printed but not linked: 5
- Summary points on quarterly (October to December. 2008) and financial year (2007/08) acute Trust Clostridium difficile data. Key points: analyses of quarterly mandatory Clostridium difficile surveillance data. Health Protection Agency [online] , (2008).
- Thompson, A. et al. in Ninth Biennial Congress of the Anaerobe Society of Americas. PII-14 (Long Beach, California, 2008).
- Angulo, F. et al. in Second International Clostridium difficile Symposium. P5 (Maribor, Slovenia, 2007).
- Louie, T. et al. in The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. K-425a (Chicago, Illinois, 2007).
- Merrigan, M. M., Gerding, D. N. & Vedantam, G. in Eighth Biennial Conference of the Anaerobe Society of America. PI-12 (Boise, Idaho, 2006).
Cited by
Items 301–400 of 999
Chemical Probes of Surface Layer Biogenesis in Clostridium difficile
Dang, T. H. T., de la Riva, L., Fagan, R. P., Storck, E. M., Heal, W. P., Janoir, C., Fairweather, N. F., & Tate, E. W. (2010) · ACS Chemical Biology · doi:10.1021/cb9002859 · Cited by 87
“SlpA[1-362] includes the LMW SLP and the N-terminal part of the HMW SLP sufficient for interaction with the LMW SLP (termed the HMW interaction domain, HID, Fig.”
BackgroundPirš, T., Avberšek, J., Zdovc, I., Krt, B., Andlovic, A., Lejko-Zupanc, T., Rupnik, M., & Ocepek, M. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.058875-0 · Cited by 66
“Clostridium difficile has been well established as a cause of human intestinal disease and, until recently, has been mostly seen as a hospital-acquired infection in elderly patients following antibiotic treatment in hospitals (Bartlett, 1992; Rupnik et al., 2009).”
BackgroundInfluentialBoth Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores
Allen, C. A., Babakhani, F., Sears, P., Nguyen, L., & Sorg, J. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01611-12 · Cited by 68
“Clostridium difficile, a Gram-positive, spore-forming, obligate anaerobe, causes intestinal infections, usually in people who have recently completed antibiotic therapies for unrelated conditions (1).”
BackgroundBabakhani, F., Gomez, A., Robert, N., & Sears, P. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00104-11 · Cited by 63
“Current standard therapies for CDI are inadequate and often result in disease recurrence that can lead to multiple episodes in some individuals (12, 16).”
BackgroundVuotto, C., Moura, I. B., Barbanti, F., Donelli, G., & Spigaglia, P. (2015) · Pathogens and Disease · doi:10.1093/femspd/ftv114 · Cited by 69
Knippel, R. J., Wexler, A. G., Miller, J. M., Beavers, W. N., Weiss, A., de Crécy-Lagard, V., Edmonds, K. A., Giedroc, D. P., & Skaar, E. P. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.015 · Cited by 62
“colon, causing disease that can progress to pseudomembranous colitis or, in serious cases, death (Rupnik et al., 2009).”
BackgroundClostridium difficile MazF Toxin Exhibits Selective, Not Global, mRNA Cleavage
Rothenbacher, F. P., Suzuki, M., Hurley, J., Montville, T. J., Kirn, T. J., Ouyang, M., & Woychik, N. A. (2012) · Journal of Bacteriology · doi:10.1128/jb.00217-12 · Cited by 62
“Progressively more cases of community-acquired (versus nosocomial) disease are being documented, and the number of cases in those who were considered to be at low risk of acquiring infections (generally healthy individuals who were not in hospitals or taking antibiotics) is also rising (43).”
BackgroundInfluentialSporulation studies in Clostridium difficile
Burns, D. A., & Minton, N. P. (2011) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2011.07.017 · Cited by 88
“In the United States of America alone, CDI is estimated to affect over 500,000 people each year and is estimated to cost the healthcare system over $3 billion per year (Cloud and Kelly, 2007; Rupnik et al., 2009).”
Backgroundvan Eijk, E., Anvar, S. Y., Browne, H. P., Leung, W. Y., Frank, J., Schmitz, A., Roberts, A. P., & Smits, W. K. (2015) · BMC Genomics · doi:10.1186/s12864-015-1252-7 · Cited by 77
“difficile can overgrow and cause potentially fatal disease [2,3].”
BackgroundGlobal Transcriptional Response of Clostridium difficile Carrying the ϕCD38-2 Prophage
Sekulović, O., & Fortier, L. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.03656-14 · Cited by 77
Toxin-Producing Clostridium difficile Strains as Long-Term Gut Colonizers in Healthy Infants
Adlerberth, I., Huang, H., Lindberg, E., Åberg, N., Hesselmar, B., Saalman, R., Nord, C. E., Wold, A. E., & Weintraub, A. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01701-13 · Cited by 62
“In severe cases, the gut wall may be perforated, a condition with high mortality (1, 2).”
BackgroundUsing an Endogenous CRISPR-Cas System for Genome Editing in the Human Pathogen Clostridium difficile
Maikova, A., Kreis, V., Boutserin, A., Severinov, K., & Soutourina, O. A. (2019) · Applied and Environmental Microbiology · doi:10.1128/aem.01416-19 · Cited by 72
“difficile to colonize the intestinal tract after the germination of preexisting or acquired spores (2, 6).”
BackgroundCafardi, V., Biagini, M., Martinelli, M., Leuzzi, R., Rubino, J. T., Cantini, F., Norais, N., Scarselli, M., Serruto, D., & Unnikrishnan, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081306 · Cited by 61
“such as pseudomembranous colitis and toxic megacolon [1,2].”
BackgroundThe Case against Antibiotics and for Anti-Virulence Therapeutics
Hotinger, J. A., Morris, S. T., & May, A. E. (2021) · Microorganisms · doi:10.3390/microorganisms9102049 · Cited by 64
“Disease symptoms, mainly caused by toxins A and B, range from diarrhea and fever in mild cases to colitis, toxic megacolon, multiorgan failure, and even death in more severe cases [104].”
BackgroundClostridium difficile Spore-Macrophage Interactions: Spore Survival
Paredes‐Sabja, D., Cofré-Araneda, G., Brito-Silva, C., Pizarro‐Guajardo, M., & Sarker, M. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043635 · Cited by 83
“neutrophils and the formation of pseudo-membranes [2].”
Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance
Mullane, K. M. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313511285 · Cited by 77
“difficile strains with reduced susceptibility to metronidazole have been reported and treatment failures have increased from a reported 3% prior to the year 2000 to 16–38% after 2000 [Aslam et al. 2005; Baines et al. 2008; Rupnik et al. 2009].”
BackgroundMolecular Characterization of Clostridium difficile Isolates from Human Subjects and the Environment
Tian, T.-T., Zhao, J., Yang, J., Qiang, C., Li, Z., Chen, J., Xu, K., Ciu, Q.-Q., & Li, R.-X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151964 · Cited by 63
“infection may range from asymptomatic colonization and self-limiting diarrhea to pseudomembranous colitis and even death [2].”
BackgroundMora-Uribe, P., Miranda-Cárdenas, C., Castro-Córdova, P., Gil, F., Calderón, I. L., Fuentes, J. A., Rodas, P. I., Banawas, S., Sarker, M. R., & Paredes‐Sabja, D. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00099 · Cited by 66
“The clinical manifestation of C. difficile infections (CDI) vary from mild to severe diarrhea, which can lead to fulminant colitis, toxic megacolon, bowel perforation, sepsis and death (Rupnik et al., 2009).”
BackgroundUpdates to Clostridium difficile Spore Germination
Kochan, T. J., Foley, M. H., Shoshiev, M. S., Somers, M. J., Carlson, P. E., & Hanna, P. C. (2018) · Journal of Bacteriology · doi:10.1128/jb.00218-18 · Cited by 78
Major Depressive Disorder and Gut Microbiota: Role of Physical Exercise
de Souza, P. B., Borba, L. A., de Jesus, L. C., Valverde, A. P., Gil‐Mohapel, J., & Rodrigues, A. L. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316870 · Cited by 73
Genetic risk factors forClostridium difficileinfection in ulcerative colitis
Ananthakrishnan, A. N., Oxford, E., Nguyen, D. D., Sauk, J. S., Yajnik, V., & Xavier, R. J. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12425 · Cited by 61
“through the actions of two enterotoxins that catalyse glucosylation of Rho proteins leading to cytoskeletal disruption.(8) The resultant inflammatory response is mediated through several innate immunity pathways including those involving NF-jB and MAP kinase signalling.”
BackgroundHigh prevalence of toxigenic Clostridium difficile in public space lawns in Western Australia
Moono, P., Lim, S., & Riley, T. V. (2017) · Scientific Reports · doi:10.1038/srep41196 · Cited by 60
Bakker, G. J., & Nieuwdorp, M. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0008-2017 · Cited by 60
Soutourina, O. A., Dubois, T., Monot, M., Shelyakin, P. V., Saujet, L., Boudry, P., Gelfand, M. S., Dupuy, B., & Martin‐Verstraete, I. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01939 · Cited by 62
Tulli, L., Marchi, S., Petracca, R., Shaw, H. A., Fairweather, N. F., Scarselli, M., Soriani, M., & Leuzzi, R. (2013) · Cellular Microbiology · doi:10.1111/cmi.12139 · Cited by 59
“Clostridium difficile is a Gram-positive, spore-forming, obligate anaerobe that is the most common cause of nosocomial diarrhoea and pseudomembranous colitis (Kelly and LaMont, 2008; Rupnik et al., 2009; Carroll and Bartlett, 2011).”
BackgroundInfluentialPatel, N. C., Griesbach, C. L., DiBaise, J. K., & Orenstein, R. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.04.022 · Cited by 68
“This includes resistance to the newer antimicrobial fidaxomicin, which was previously reported to decrease recurrent CDI of less virulent strains.(19,20) Although we did not collect specific data on strain types, in general, less than 25% of CDI cases at Mayo Clinic in Arizona are NAP1.”
BackgroundClostridium difficile Spores: A Major Threat to the Hospital Environment
Barra, J., & Paredes‐Sabja, D. (2014) · Future Microbiology · doi:10.2217/fmb.14.2 · Cited by 64
Ultrastructural Variability of the Exosporium Layer of Clostridium difficile Spores
Pizarro‐Guajardo, M., Calderón-Romero, P., Castro-Córdova, P., Mora-Uribe, P., & Paredes‐Sabja, D. (2016) · Applied and Environmental Microbiology · doi:10.1128/aem.03410-15 · Cited by 59
“Clostridium difficile is a leading cause of nosocomial antibioticassociated diarrhea in developed and developing countries (1, 2, 5).”
BackgroundEquine faecal microbiota transplant: Current knowledge, proposed guidelines and future directions
Mullen, K. R., Yasuda, K., Divers, T. J., & Weese, J. S. (2016) · Equine Veterinary Education · doi:10.1111/eve.12559 · Cited by 72
“Clostridium difficile causes infection by production of toxins that destroy the intestinal epithelium leading to severe inflammation and secretory diarrhoea (Rupnik et al. 2009).”
BackgroundUpdate on Clostridium difficile infection
O’Donoghue, C., & Kyne, L. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283411634 · Cited by 59
The Epidemiology of Clostridium difficile Infection in Japan: A Systematic Review
Riley, T. V., & Kimura, T. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0186-1 · Cited by 69
“INTRODUCTION Clostridium difficile is the most common infective cause of nosocomial diarrhea, implicated in 20–30% of cases of antibiotic-associated diarrhea [1, 2].”
BackgroundClostridium Difficile Infection in Older Adults: A Review and Update on Its Management
Kee, V. R. (2012) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.12.004 · Cited by 58
A proposed nomenclature for cell wall proteins of Clostridium difficile
Fagan, R. P., Janoir, C., Collignon, A., Mastrantonio, P., Poxton, I. R., & Fairweather, N. F. (2011) · Journal of Medical Microbiology · doi:10.1099/jmm.0.028472-0 · Cited by 58
Molecular epidemiology of Clostridium difficile in a tertiary hospital of China
Chen, Y., Gu, S., Wei, Z., Shen, P., Kong, H.-S., Yang, Q., & Li, L. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.068668-0 · Cited by 58
“C. difficile infection has increased markedly in the last decade and is regarded as the leading cause of nosocomial diarrhoea among adults in developed countries (Rupnik et al., 2009).”
BackgroundInfluentialBaldoni, D., Gutierrez, M. M., Timmer, W., & Dingemanse, J. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt401 · Cited by 58
Valdés-Varela, L., Alonso‐Guervós, M., García‐Suárez, O., Gueimonde, M., & Ruas‐Madiedo, P. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00577 · Cited by 65
“…Spain, 3 Department of Morphology and Cellular Biology, University of Oviedo, Oviedo, Spain Clostridium difficile is an opportunistic pathogen inhabiting the human gut, often being the aetiological agent of infections after a microbiota dysbiosis following, for example, an antibiotic treatment.”
BackgroundPrevalence of Clostridium difficilein raw beef, cow, sheep, goat, camel and buffalo meat in Iran
Rahimi, E., Jalali, M., & Weese, J. S. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-119 · Cited by 57
“difficile found in animals and humans are often indistinguishable [10-12] raising concerns that C.”
BackgroundSekulović, O., Garneau, J. R., Néron, A., & Fortier, L. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.00237-14 · Cited by 72
“Other virulence factors, like a binary toxin (CDT) and various cell surface proteins, possibly contribute to the overall virulence of this species as well (3).”
BackgroundClostridium difficile in a HIV-infected cohort
Haines, C. F., Moore, R. D., Bartlett, J. G., Sears, C. L., Cosgrove, S. E., Carroll, K. C., & Gebo, K. A. (2013) · AIDS · doi:10.1097/01.aids.0000432450.37863.e9 · Cited by 57
“First, CDI incidence in the general population is increasing and may contribute to the increased incidence in our study [17].”
BackgroundCitron, D. M., Tyrrell, K. L., Merriam, C. V., & Goldstein, E. J. C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06305-11 · Cited by 57
“It is also seen increasingly in outpatients, including pregnant and postpartum women and people without previous antibiotic exposure (24, 25).”
BackgroundJasni, A. S., Mullany, P. P., Hussain, H. A., & Roberts, A. P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00496-10 · Cited by 57
“Clostridium difficile is an enteric pathogen and the leading cause of antibiotic-associated diseases ranging from self-limiting diarrhea to severe pseudomembranous colitis (7, 10, 19).”
BackgroundDelgado, A., Reveles, I. A., Cabello, F. T., & Reveles, K. R. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2553-z · Cited by 54
“CDI results in frequent diarrhea, but may also progress to megacolon, ileus, sepsis, or even death [2].”
BackgroundInteractions between the microbiota and innate and innate-like lymphocytes
Constantinides, M. G. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ri0917-378r · Cited by 57
Gencic, S., & Grahame, D. A. (2020) · Journal of Bacteriology · doi:10.1128/jb.00233-20 · Cited by 56
Immune responses induced by Clostridium difficile
Péchiné, S., & Collignon, A. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.04.014 · Cited by 59
Current knowledge on the laboratory diagnosis ofClostridium difficileinfection
Martínez-Meléndez, A., Camacho-Ortíz, A., Morfín‐Otero, R., Maldonado-Garza, H. J., Villarreal-Treviño, L., & Garza‐González, E. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i9.1552 · Cited by 58
Microbe–microbe interactions during Clostridioides difficile infection
Abbas, A. A., & Zackular, J. P. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.01.016 · Cited by 60
Stevens, V. W., Dumyati, G. K., Brown, J. E., & van Wijngaarden, E. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2198 · Cited by 67
Song, L., Zhao, M., Duffy, D. C., Hansen, J., Shields, K. S., Wungjiranirun, M., Chen, X., Xu, H. J., Leffler, D. A., Sambol, S. P., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.01334-15 · Cited by 60
Recent insights into Clostridium difficile pathogenesis
Peniche, A. G., Savidge, T., & Dann, S. M. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000433318.82618.c6 · Cited by 70
“but also on community alterations in the gut microbiota and host responses [1,2].”
BackgroundThe divergent roles of sortase in the biology of Gram-positive bacteria
Susmitha, A., Bajaj, H., & Nampoothiri, K. M. (2021) · The Cell Surface · doi:10.1016/j.tcsw.2021.100055 · Cited by 56
“It causes antibiotic-associated diarrhoea and severe inflammation in the intestines (Rupnik et al., 2009).”
BackgroundClostridium difficile Infection in Humans and Piglets: A ‘One Health’ Opportunity
Squire, M. M., & Riley, T. V. (2012) · Current topics in microbiology and immunology · doi:10.1007/82_2012_237 · Cited by 61
The tide of antimicrobial resistance and selection
Wilcox, M. H. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(09)70550-3 · Cited by 55
Guo, S., Yan, W., McDonough, S. P., Lin, N., Wu, K. J., He, H., Xiang, H., Yang, M., Moreira, M. A. S., & Chang, Y. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.02.006 · Cited by 57
Citron, D. M., Tyrrell, K. L., Merriam, C. V., & Goldstein, E. J. C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05655-11 · Cited by 56
“CDI has increased in prevalence and severity during the last decade, resulting in increased mortality and complications, recurrent disease, and prolonged hospital stays (7, 17).”
BackgroundClostridium Difficile Infection in Children: A Review
Borali, E., & Giacomo, C. D. (2016) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001264 · Cited by 61
“The management of CD infection involves 3 basic principles: (1) supportive care, (2) discontinuation of the precipitating antibiotic(s), and (3) the initiation of effective anti-CD therapy, where necessary (some studies show that a significant number of patients did not require treatment) (13,68).”
Treatment of recurrent Clostridium difficile colitis: a narrative review
Hopkins, R. J., & Wilson, R. B. (2017) · Gastroenterology report · doi:10.1093/gastro/gox041 · Cited by 63
“cause of infectious diarrhoea in hospitalized patients [3,4].”
BackgroundClostridioides difficile ferrosome organelles combat nutritional immunity
Pi, H., Sun, R., McBride, J. R., Kruse, A. R. S., Gibson-Corley, K. N., Krystofiak, E. S., Nicholson, M. R., Spraggins, J. M., Zhou, Q., & Skaar, E. P. (2023) · Nature · doi:10.1038/s41586-023-06719-9 · Cited by 54
“Current treatments are limited to last resort antibiotics, such as fidaxomicin or vancomycin, and in more serious cases faecal microbiota transplantation or surgery 10,11 .”
BackgroundSchneeberg, A., Neubauer, H., Schmoock, G., Großmann, E., & Seyboldt, C. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.056473-0 · Cited by 62
Hernandez, L. D., Racine, F., Xiao, L., DiNunzio, E. N., Hairston, N. N., Sheth, P. R., Murgolo, N., & Therien, A. G. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04433-14 · Cited by 54
“Clinical isolates of C. difficile were obtained from M. Wilcox (United Kingdom), M. Miller (Canada), D. Gerding (United States), H. Kato (Japan), or tgcBIOMICS (western Europe) (for a complete list, see Table S1 in the supplemental material).”
BackgroundInfluentialHype or hypervirulence: A reflection on problematicC. difficilestrains
Smits, W. K. (2013) · Virulence · doi:10.4161/viru.26297 · Cited by 56
“difficile is that no single factor (toxins, sporulation, or resistance) is responsible for the increased virulence of epidemic strains, though at least one of the major clostridial toxins is required.(4) What then determines the successfulness of C.”
BackgroundPractice Parameters for the Management of Clostridium difficile Infection
Steele, S. R., McCormick, J., Melton, G. B., Paquette, I. M., Rivadeneira, D. E., Stewart, D., Buie, W. D., & Rafferty, J. L. (2014) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000289 · Cited by 58
Genetic markers for Clostridium difficile lineages linked to hypervirulence
Knetsch, C. W., Hensgens, M. P. M., Harmanus, C., van der Bijl, M. W., Savelkoul, P. H. M., Kuijper, E. J., Corver, J., & van Leeuwen, H. C. (2011) · Microbiology · doi:10.1099/mic.0.051953-0 · Cited by 54
“This variability, in combination with multiple copies of the rDNA, results in different amplicons after PCR amplification, which are referred to as PCR ribotypes (Bidet et al., 1999; Rupnik et al., 2009).”
BackgroundPrevalence and molecular epidemiology of Clostridium difficile infection in Thailand
Putsathit, P., Maneerattanaporn, M., Piewngam, P., Kiratisin, P., & Riley, T. V. (2016) · New Microbes and New Infections · doi:10.1016/j.nmni.2016.10.004 · Cited by 54
“difficile is the production of toxins A and B [1].”
BackgroundMethodInfluentialMolecular Characterization of Clostridium difficile Isolates in China From 2010 to 2015
Liu, X.-S., Li, W., Zhang, W., Wu, Y., & Lu, J. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00845 · Cited by 54
“Keywords: Clostridium difficile, MLST, toxin genes profile, PCR-ribotyping, molecular characterization INTRODUCTION Clostridium difficile is considered to be the leading cause of antimicrobial-associated diarrhea and has been observed in older inpatients (Rupnik et al., 2009).”
BackgroundBarbut, F., Galperine, T. K., Vanhems, P., Monnier, A. L., Durand-Gasselin, B., Canis, F., Jeanbat-Mimaud, V., Duburcq, A., Alami, S., Bensoussan, C., et al. (2019) · Health and Quality of Life Outcomes · doi:10.1186/s12955-019-1081-5 · Cited by 54
“Background Clostridium difficile is an anaerobic Gram-positive bacterium responsible for 15–25% of cases of post-antibiotic diarrhea and virtually all cases of pseudomembranous colitis [1, 2].”
BackgroundAllegretti, J. R., Kelly, C. R., Grinspan, A. M., Mullish, B. H., Hurtado, J., Carrellas, M., Marcus, J., Marchesi, J. R., McDonald, J. A. K., Gerardin, Y., et al. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa283 · Cited by 59
Boekhoud, I. M., Sidorov, I. A., Nooij, S., Harmanus, C., Sanders, I. M. J. G., Viprey, V. F., Spittal, W. D., Clark, E., Davies, K., Freeman, J., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab097 · Cited by 56
Frädrich, C., Beer, L.-A., & Gerhard, R. (2016) · Toxins · doi:10.3390/toxins8010025 · Cited by 56
“The intestinal disease ranges from asymptomatic colonization to mild diarrhoea and more severe disease syndromes including pseudomembranous colitis or in rare cases toxic megacolon [1].”
BackgroundEscobar-Cortés, K., Barra, J., & Paredes‐Sabja, D. (2013) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2013.01.016 · Cited by 53
Himsworth, C. G., Patrick, D. M., Mak, S., Jardine, C. M., Tang, P., & Weese, J. S. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.03609-13 · Cited by 58
“For this reason, disease in humans is often precipitated by the administration of antibiotics (3, 6).”
BackgroundInfluentialDiagnostic Pitfalls in Clostridium difficile Infection
Planche, T., & Wilcox, M. H. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2014.11.008 · Cited by 53
Clostridium difficile infection in HIV-seropositive individuals and transplant recipients
Collini, P., Bauer, M. P., Kuijper, E. J., & Dockrell, D. H. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.12.003 · Cited by 58
Intrinsic Class D β-Lactamases of Clostridium difficile
Tóth, M., Stewart, N. K., Smith, C. A., & Vakulenko, S. B. (2018) · mBio · doi:10.1128/mbio.01803-18 · Cited by 59
“Enzymea Amino acid substitutions CDD-1 (41)b S2 V3 I5 G14 C22 D74 N103 S109 D165 R177 R205 L214 CDD-1-M1 (6) Y CDD-2 (312) K I M Y E D CDD-2-M1 (22) K I M Y E D C CDD-2-M2 (13) K I M Y E D I CDD-2-M3 (11) K I M Y E D Y CDD-2-M4 (24) K I M Y E Y CDD-2-M5 (9) K I M Y E CDD-2-M6 (16) K I M D Y E Y CDD-2-M7 (23) K I Y N K”
Current Insights on the Diverse Structures and Functions in Bacterial Collagen-like Proteins
Qiu, Y., Zhai, C., Chen, L., Liu, X., & Yeo, J. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00018 · Cited by 53
Clostridium difficile PCR Ribotype 018, a Successful Epidemic Genotype
Baldan, R., Trovato, A., Bianchini, V., Biancardi, A., Cichero, P., Mazzotti, M. F., Nizzero, P., Moro, M., Ossi, C. M., Scarpellini, P., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00533-15 · Cited by 52
Bioavailability of the anti-clostridial bacteriocin thuricin CD in gastrointestinal tract
Rea, M. C., Alemayehu, D., Casey, P. G., O’Connor, P. M., Lawlor, P. G., Walsh, M., Shanahan, F., Kiely, B., Ross, R. P., & Hill, C. (2013) · Microbiology · doi:10.1099/mic.0.068767-0 · Cited by 57
“Moreover, it is also responsible for up to 25 % of all cases of antibiotic associated diarrhoea, with the elderly being most at risk (for a review see Rupnik et al., 2009).”
BackgroundMurase, T., Eugenio, L., Schorr, M., Hussack, G., Tanha, J., Kitova, E. N., Klassen, J. S., & Ng, K. K.-S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.505917 · Cited by 56
“Infection of the large intestine by the obligate anaerobic bacterium Clostridium difficile is one of the most common and costly hospital-acquired diseases worldwide (1, 2).”
BackgroundLakshminarayanan, B., Harris, H. M. B., Coakley, M., O’Sullivan, Ó., Stanton, C., Pruteanu, M., Shanahan, F., O’Toole, P. W., Ross, R. P., & on behalf of the ELDERMET consortium (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.052258-0 · Cited by 52
“may be responsible for serious infections including mild to severe diarrhoea and pseudomembranous colitis caused by Clostridium difficile (Rupnik et al., 2009) or foodborne Abbreviation: OTU, operational taxonomic unit.”
BackgroundCausal discovery for the microbiome
Corander, J., Hanage, W. P., & Pensar, J. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00186-0 · Cited by 59
Effects of bacteriophages on gut microbiome functionality
Kurilovich, E., & Geva-Zatorsky, N. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2481178 · Cited by 51
“125 Though its toxin genes are commonly considered chromosomal, data has been accumulating showing a crucial role of prophages in C. difficile toxicity regulation and spread.”
RecurrentClostridium difficileinfections: The importance of the intestinal microbiota
Terrier, M.-C. Z., Simonet, M. L., Bichard, P., & Frossard, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7416 · Cited by 62
Fecal transplant policy and legislation
Vyas, D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.6 · Cited by 51
Taur, Y., & Pamer, E. G. (2014) · Nature Medicine · doi:10.1038/nm.3492 · Cited by 56
Clostridium difficile: controversies and approaches to management
Bauer, M. P., van Dissel, J. T., & Kuijper, E. J. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32833229ce · Cited by 56
Peláez, T., Alcalá, L., Blanco, J. L., Álvarez‐Pérez, S., Marín, M., Martín, A., Catalán, P., Reigadas, E., García, M. E., & Bouza, E. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.05.009 · Cited by 59
Regulation of Clostridium difficile Spore Formation by the SpoIIQ and SpoIIIA Proteins
Fimlaid, K. A., Jensen, O., Donnelly, M. L., Siegrist, M. S., & Shen, A. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005562 · Cited by 57
Yoon, S., Yu, J., McDowell, A., Kim, S. H., You, H. J., & Ko, G. (2017) · Journal of Microbiology · doi:10.1007/s12275-017-7340-4 · Cited by 49
Friedman-Korn, T., Livovsky, D. M., Maharshak, N., Cohen, N. A., Paz, K., Shitrit, A. B., Goldin, E., & Koslowsky, B. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4833-2 · Cited by 58
“CDI is estimated to occur in eight out of 100,000 people per year [1, 2].”
Discovery of new type I toxin–antitoxin systems adjacent to CRISPR arrays in Clostridium difficile
Maikova, A., Johann, P., Boudry, P., Hajnsdorf, E., Kint, N., Monot, M., Poquet, I., Martin‐Verstraete, I., Dupuy, B., & Soutourina, O. A. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky124 · Cited by 62
“difficile from preexisting or acquired spores (10,11).”
A retrospective study of community-acquired Clostridium difficile infection in southwest China
Liao, F., Li, W., Gu, W., Zhang, W., Liu, X., Fu, X., Xu, W. B., Wu, Y., & Lu, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-21762-7 · Cited by 51
Structure of the pore forming fragment of Clostridium difficile toxin B in complex with VHH 5D
Chen, P., Lam, K. H., & Jin, R. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6oq6/pdb · Cited by 52
Phetcharaburanin, J., Hong, H. A., Colenutt, C., Bianconi, I., Sempere, L., Permpoonpattana, P., Smith, K., Dembek, M., Tan, S., Brisson, M., et al. (2014) · Molecular Microbiology · doi:10.1111/mmi.12611 · Cited by 57
“Disease is caused mainly by the production of two toxins,A(TcdA) and B (TcdB), which leads to diarrhoea and in more severe cases, pseudomembrane colitis (Rupnik et al., 2009).”
BackgroundInfluentialClostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis
Alonso, C. D., & Marr, K. A. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283630c4c · Cited by 51
Lipoprotein CD0873 Is a Novel Adhesin of Clostridium difficile
Kovacs-Simon, A., Leuzzi, R., Kasendra, M. J., Minton, N. P., Titball, R. W., & Michell, S. L. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu070 · Cited by 68
“bacterial proteins, with other macromolecules possibly playing direct or indirect roles in attachment [5].”
BackgroundProspective study of bacteraemia in acute haemorrhagic diarrhoea syndrome in dogs
Unterer, S., Lechner, E., Mueller, R. S., Wolf, G., Straubinger, R. K., Schulz, B. S., & Hartmann, K. (2015) · Veterinary Record · doi:10.1136/vr.102521 · Cited by 63
Probiotics to preventStaphylococcus aureusdisease?
Piewngam, P., & Otto, M. J. (2019) · Gut Microbes · doi:10.1080/19490976.2019.1591137 · Cited by 64
“Infection with Clostridium difficile (CDI), a leading cause of healthcare-associated morbidity and mortality worldwide, is a posterchild example of disease that is caused by the depletion of intestinal microbiota by antibiotics.(4) The contribution of the microbiota to host defense against pathogen colonization and ov…”
BackgroundDu, P., Cao, B., Wang, J., Li, W. G., Jia, H., Zhang, W., Lu, J., Li, Z., Yu, H., Chen, C., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03487-13 · Cited by 49
Pai, S., Aliyu, S. H., Enoch, D., & Karas, J. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051728 · Cited by 50
“[11,26] Only five (7%) of our patients were on PPIs prior to the onset of symptoms and 19 (25%) had recently received H2 receptor antagonists.”
BackgroundAllosteric regulation of protease activity by small molecules
Shen, A. (2010) · Molecular BioSystems · doi:10.1039/c003913f · Cited by 54
Metadata
- Authors
- Rupnik, M., Wilcox, M. H., & Gerding, D. N.
- Affiliations
- University of Maribor (SI)
- Leeds General Infirmary (GB)
- Loyola University Chicago (US)
- Venue
- Nature Reviews Microbiology
- Published
- 2009-07
- Volume
- 7
- Issue
- 7
- Pages
- 526-536
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W1968953113
- Cited by
- 1,380
- References
- 124
- Citations by year
- 2026: 18 · 2025: 36 · 2024: 49 · 2023: 59 · 2022: 74 · 2021: 72 · 2020: 88 · 2019: 78 · 2018: 109 · 2017: 104 · 2016: 107 · 2015: 107 · 2014: 133 · 2013: 141 · 2012: 93
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- Clostridium difficile infection, nosocomial infections, virulence factors, epidemiology, pathogenesis, community-acquired infections, food-producing animals, antibiotic-associated diarrhea, clinical outcomes, infection prevention and treatment
- MeSH terms
- Animals, Anti-Bacterial Agents, Enterocolitis, Pseudomembranous, Humans, Models, Theoretical, Clostridioides difficile, Virulence Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.